The hepatic apelin system: A new therapeutic target for liver disease

Hepatology

Volumn 49, Issue 3, 2009, Pages 1055-

  Dogru, Teoman ^a   Ercin, Cemal Nuri ^a   Erdem, Gokhan ^a   Kilciler, Guldem ^a   Tapan, Serkan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN 1 RECEPTOR; APELIN; APELIN RECEPTOR; GLUCOSE; INSULIN; APLN PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANGIOGENESIS; BLOOD PRESSURE; BODY MASS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LETTER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY;

DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER DISEASES; OBESITY;

EID: 63349093419     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22688     Document Type: Letter

References (10)

1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-476.
2. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004;118:119-125.
3. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, Morales-Ruiz M, et al. The hepatic apelin system: A new therapeutic target for liver disease. HEPATOLOGY 2008;48:1193-1201.
4. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007;76:24-29.
5. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006;114:544-548.
6. Sung SH, Chuang SY, Sheu WH, Lee WJ, Chou P, Chen CH. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. Hypertens Res 2008;31:633-640.
7. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-1771.
8. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007;115:428-432.
9. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:289-292.
10. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2008; doi:10.1016/ j.atherosclerosis.2008.08.030.